Aptamer Group has entered a funded development and licensing agreement with a global life sciences company to create an Optimer®-Fc reagent for diagnostic kits. The deal includes royalties on future sales, supporting Aptamer’s recurring revenue growth...
Aptamer Group plc has partnered with Unilever for a second Optimer program, aiming to innovate body odour control solutions in the personal care market...
Aptamer Group plc announces promising new data on its Optimer therapeutic delivery platform for liver fibrosis, showcasing broad therapeutic potential across various diseases...
Aptamer Group announces a breakthrough in Alzheimer's diagnostics with a new ELISA test utilising saliva samples, enhancing accessibility and rapid detection...
Aptamer Group plc has secured a significant global licensing deal with the University of Glasgow, advancing synthetic binders for vaccines in swine health...
Aptamer Group plc has released a new corporate presentation and investor factsheet, showcasing its strategic growth, operational progress, and financial performance in the life science industry...
Aptamer Group plc reports impressive interim results for H1 2025, highlighting revenue growth and strategic advancements in life sciences innovation...
Aptamer Group plc reports progress on key projects in its H1 2025 trading update, highlighting partnerships with Unilever and Alzheimer's biomarker validation...
Aptamer Group plc (LON: APTA) secures a £155,000 contract to develop Optimer® binders for a rare disease biopharma, boosting clinical trial capabilities...
Aptamer Group plc enhances its Scientific Advisory Board with three leading experts to drive innovation and commercialization in targeted therapy solutions...
Aptamer Group plc is set to host its AGM, highlighting progress in cost reduction, commercial growth, and high-profile partnerships in life sciences...
Aptamer Group plc (LON:APTA) secures £471,000 in new contracts, reinforcing its market position by expanding partnerships with leading pharmaceutical firms...
Aptamer Group has entered a funded development and licensing agreement with a global life sciences company to create an Optimer®-Fc reagent for diagnostic kits. The deal includes royalties on future sales, supporting Aptamer’s recurring revenue growth...
Aptamer Group plc has partnered with Unilever for a second Optimer program, aiming to innovate body odour control solutions in the personal care market...
Aptamer Group plc announces promising new data on its Optimer therapeutic delivery platform for liver fibrosis, showcasing broad therapeutic potential across various diseases...
Aptamer Group announces a breakthrough in Alzheimer's diagnostics with a new ELISA test utilising saliva samples, enhancing accessibility and rapid detection...
Aptamer Group plc has secured a significant global licensing deal with the University of Glasgow, advancing synthetic binders for vaccines in swine health...
Aptamer Group plc has released a new corporate presentation and investor factsheet, showcasing its strategic growth, operational progress, and financial performance in the life science industry...
Aptamer Group plc reports impressive interim results for H1 2025, highlighting revenue growth and strategic advancements in life sciences innovation...
Aptamer Group plc reports progress on key projects in its H1 2025 trading update, highlighting partnerships with Unilever and Alzheimer's biomarker validation...
Aptamer Group plc (LON: APTA) secures a £155,000 contract to develop Optimer® binders for a rare disease biopharma, boosting clinical trial capabilities...
Aptamer Group plc enhances its Scientific Advisory Board with three leading experts to drive innovation and commercialization in targeted therapy solutions...
Aptamer Group plc is set to host its AGM, highlighting progress in cost reduction, commercial growth, and high-profile partnerships in life sciences...
Aptamer Group plc (LON:APTA) secures £471,000 in new contracts, reinforcing its market position by expanding partnerships with leading pharmaceutical firms...
